Emerging data suggest Retatrutide , a dual agonist targeting both the gut-brain axis and GIP , may represent a notable advancement for weight loss . Initial patient trials have shown substantial https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide